非人源聚糖可调控小鼠抗凝血因子VIII抗体形成
本研究探讨重组凝血因子VIII(FVIII)产品免疫原性差异的机制,发现BHK细胞比CHO细胞表达更高水平的非人源碳水化合物α1-3半乳糖(αGal),BHK来源FVIII携带更多αGal并与抗αGal抗体反应增强。在可自发产生抗αGal抗体的αGal敲除小鼠中,输注BHK来源而非CHO来源FVIII导致显著更高的抗FVIII抗体形成,提示重组FVIII产品的非人源碳水化合物翻译后修饰可影响抗FVIII抗体产生。
要点
- BHK细胞比CHO细胞表达更高水平的非人源αGal。
- BHK来源FVIII携带更多αGal,与抗αGal抗体反应增强。
- αGal敲除小鼠中BHK来源FVIII诱导更强的抗FVIII抗体形成。
核心结论
- 重组FVIII产品上的非人源碳水化合物翻译后修饰可能影响抗FVIII抗体的形成。
研究设计与样本
- 研究比较BHK与CHO细胞αGal表达水平及来源FVIII的αGal含量与抗体反应性。
- 在αGal敲除小鼠中比较输注BHK来源与CHO来源FVIII后抗FVIII抗体形成。
主要发现
- BHK细胞表达的非人源αGal水平高于CHO细胞。
- BHK来源FVIII的αGal水平升高,与抗αGal抗体反应性增强相对应。
- αGal敲除小鼠输注BHK来源FVIII后抗FVIII抗体形成显著高于输注CHO来源FVIII。
临床怎么用
- 提示选择重组FVIII产品时需关注非人源聚糖修饰对免疫原性的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recombinant factor VIII (FVIII) products represent a life-saving intervention for patients with hemophilia A. However, patients can develop antibodies against FVIII that prevent its function and directly increase morbidity and mortality. The development of anti-FVIII antibodies varies depending on the type of recombinant product used, with previous studies suggesting that second-generation baby hamster kidney (BHK)-derived FVIII products display greater immunogenicity than do third-generation Chinese hamster ovary (CHO)-derived FVIII products. However, the underlying mechanisms responsible for these differences remain incompletely understood. Our results demonstrate that BHK cells express higher levels of the nonhuman carbohydrate α1-3 galactose (αGal) than do CHO cells, suggesting that αGal incorporation onto FVIII may result in anti-αGal antibody recognition that could positively influence the development of anti-FVIII antibodies. Consistent with this, BHK-derived FVIII exhibits increased levels of αGal, which corresponds to increased reactivity with anti-αGal antibodies. Infusion of BHK-derived, but not CHO-derived, FVIII into αGal-knockout mice, which spontaneously generate anti-αGal antibodies, results in significantly higher anti-FVIII antibody formation, suggesting that the increased levels of αGal on BHK-derived FVIII can influence immunogenicity. These results suggest that posttranslational modifications of recombinant FVIII products with nonhuman carbohydrates may influence the development of anti-FVIII antibodies.
引用
- Arthur CM, Zerra PE, Shin S, et al. Nonhuman glycans can regulate anti-factor VIII antibody formation in mice. Blood. 2022. PMID: 34019619. doi:10.1182/blood.2020009210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。